JNMT
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Koslowsky, I. L.
Right arrow Articles by Bitner, S. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Koslowsky, I. L.
Right arrow Articles by Bitner, S. J.
Journal of Nuclear Medicine Technology Volume 29, Number 4, 2001 197-200
© 2001 by Society of Nuclear Medicine


RADIOPHARMACY

Evaluation of the Stability of 99mTc-ECD and Stabilized 99mTc-HMPAO Stored in Syringes

Ingrid L. Koslowsky, Stephanie E. Brake and Sandra J. Bitner

Nuclear Medicine, Foothills Medical Centre, Calgary, Alberta, Canada

ABSTRACT

Objective:To determine and compare the stability of 99mTc-ECD and stabilized 99mTc-HMPAO when stored in syringes over an 8-h period.

Methods:99mTc-ECD and stabilized 99mTc-HMPAO were prepared according to the manufacturers’ protocols, with the following exception: eluate less than 60 min old was used to prepare 99mTc-HMPAO rather than the recommended 30 min. Once prepared, 185 MBq (5 mCi) of both products were drawn into 5-mL syringes and allowed to sit at room temperature. At 2, 4, 6, and 8 h after preparation, the radiochemical purity (RCP) of the contents of the syringes was determined and compared to the RCP of the products in vials. Retention of activity of each product in syringes was also evaluated by measuring activity remaining in each syringe (and filter, in the case of 99mTc-HMPAO) after expressing its contents.

Results:The RCP of stabilized 99mTc-HMPAO stored in syringes decreased from a mean of 87.7% at 2 h to 74.0% at 8 h after preparation. In contrast, 99mTc-ECD retained an RCP of greater than 94% throughout the time tested. The impurity that appeared to increase over time with 99mTc-HMPAO was found to be sodium pertechnetate. Total retention of activity remaining in the syringe and filter ranged from 11.6% at 2 h to 9.5% at 8 h for 99mTc-HMPAO; the syringe itself retained less than 5% of the total activity at all time periods. 99mTc-ECD exhibited 6.2% to 11.3% retention of activity in the syringe. The sorption of sodium pertechnetate to the syringe for the same time period was less than 1%.

Conclusions:99mTc-ECD is a more stable product than stabilized 99mTc-HMPAO in a syringe. Both products demonstrate retention of radioactivity in the syringe. Some of this retention may denote sorption of the products to plastic.

Key Words: stabilized 99mTc-HMPAO; 99mTc-ECD; stability in syringe; retention in syringe




This article has been cited by other articles:


Home page
J. Nucl. Med. Technol.Home page
M. del Carmen Plancha-Mansanet, E. Caballero-Calabuig, J. Felix-Fontestad, M. D. Reyes-Ojeda, P. Sopena-Novales, P. Abreu-Sanchez, M. del Carmen Cano-Terol, and R. Sopena-Monforte
Stability of Stabilized 99mTc-D,L-HMPAO Stored in Vials and Syringes
J. Nucl. Med. Technol., December 1, 2008; 36(4): 213 - 216.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE JOURNAL OF NUCLEAR MEDICINE JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY
Copyright © 2001 by the Society of Nuclear Medicine Technologist Section.